Morocco's sovereign fund takes Recipharm stake in vaccine maker MARBIO
What's the deal? The Mohammed VI Investment Fund (FM6I), Morocco's sovereign investment vehicle, is acquiring Recipharm's 10% stake in Maroc Biotechnologies (MARBIO)Dealroom has a profile for this one. Try Dealroom →, a domestic vaccine and biological-products manufacturer. The deal value was not disclosed. It follows a framework agreement signed on September 21, 2026, between the Kingdom of Morocco, FM6I, BAB Consortium and Recipharm ABDealroom has a profile for this one. Try Dealroom →.
Why now? MARBIO was set up in 2021 to cut Morocco's dependence on external pharmaceutical supply chains. Five years on, the company has moved from setup to industrial operations, and the buyout marks its next stage of development.
What's the endgame? The acquisition gives Morocco a stronger domestic shareholder base as it consolidates strategic industrial capabilities. For FM6I — which has an initial share capital of 15 billion dirhams — the investment fits a mandate of backing projects deemed strategic for the country's long-term growth.
What changes for MARBIO? Recipharm, a global contract development and manufacturing organisation, is exiting the project. It contributed expertise in development, manufacturing, operations and regulatory matters. The framework agreement sets out a transition designed to preserve MARBIO's operational continuity.
The company's industrial platform in Benslimane handles sterile filling and packaging for vaccines and biological products, plus formulation, quality control and batch release. The site is built as an integrated platform intended to serve markets beyond Morocco.
What could go wrong? The transaction remains subject to completion conditions and regulatory approvals. Recipharm's exit also removes a partner that supplied much of the project's technical and regulatory know-how.
The signal: The deal reflects Morocco's push to localise strategic manufacturing and prepare for future health emergencies. It is particularly relevant for Africa, where vaccine and pharmaceutical supply chains remain dependent on international production networks.
Read more: en.walaw.press
Image credit: ITB495
